Apr 01, 2021 / 01:00PM GMT
Debjit D. Chattopadhyay - Guggenheim Securities, LLC - MD & Senior Biotech Analyst
All right, I think we're live. So good morning, and welcome to the Guggenheim Healthcare Talks, our signature Genomic Medicine & Rare Disease Conference Day. This is the second of our 9 panels, and this will primarily focus on Duchenne muscular dystrophy.
I am Debjit. I'm one of the senior analysts at Guggenheim, and joining us today is Michael Binks, the Vice President of Clinical Research from Pfizer; Sam Wadsworth, Clinical -- Chief Scientific Officer at Ultragenyx; Arthur Levin, Chief Scientific Officer at Avidity, Carl Morris, Chief Scientific Officer at Solid; and Ian Estepan, Chief Financial Officer at Sarepta.
Questions and Answers:
Debjit D. Chattopadhyay - Guggenheim Securities, LLC - MD & Senior Biotech AnalystSo given we have a very packed panel, why don't I start first at Pfizer and more on sort of the challenge that we, on the outside are facing in trying to understand all the emerging data in the field. So even in younger patients, do
Trustpilot
